The phrase "advantage for either" is correct and usable in written English.
It can be used when discussing a situation where there is a potential benefit for one of two parties involved.
Example: "In this negotiation, there seems to be no advantage for either side, which makes reaching an agreement difficult."
Alternatives: "benefit for either" or "gain for either".
There is absolutely no advantage for either team in this game.
"We know Uruguay's strengths and they know about us, so there will be little surprise or advantage for either team.
No advantage for either strategy was seen, except in the group undergoing early coronary artery bypass grafting (CABG).
Of course, for many genres, including racing, third-person action adventures and moba titles like League of Legends, there should be no real interface advantage for either side.
In such a tight scenario, public opinion would have to shift across the board by only two percentage points to create a clear advantage for either side.
Although the campaign resulted in no strategic advantage for either side, it was the last time General Lee launched a large scale offensive with his army.
However, the existing literature is unable to demonstrate clear advantages for either interface, as empirical studies yielded different findings, sometimes even contradicting ones.
Their meta-analysis did not highlight clear advantages for either approach except in relation to the malunion rate, which, however, is not a key factor determining treatment selection.
The small advantages for either candidate on these individual samplings are not large enough to be considered statistically significant in isolation, and when combined by the HuffPost Pollster tracking model they continue to show a virtually tied race for the national popular vote.
Likewise, qualitative evaluation of relative cerebral blood volume and relative cerebral blood flow maps by 2 experienced blinded radiologists revealed no differences and no advantages for either of the 2 GBCAs.
The traditional limitation of a lack of power to detect mortality differences from individual trials on HAP is no longer a concern as our meta-analysis included approximately 4000 patients and allowed close to 100% power to detect a mortality or clinical response difference, thereby conferring a high degree of confidence that there are no advantages for either drug.
